Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Multiple sclerosis: Is there a safe time to discontinue therapy in MS?

× No keyword cloud information.

7 in total

Review 1. Stopping immunomodulatory medications in MS: Frequency, reasons and consequences.

Authors: W O Tobin; B G Weinshenker
Journal: Mult Scler Relat Disord Date: 2015-07-08 Impact factor: 4.339

Review 2. Moving toward earlier treatment of multiple sclerosis: Findings from a decade of clinical trials and implications for clinical practice.

Authors: Mark S Freedman; Giancarlo Comi; Nicola De Stefano; Frederik Barkhof; Chris H Polman; Bernard M J Uitdehaag; Lorenz Lehr; Bettina Stubinski; Ludwig Kappos
Journal: Mult Scler Relat Disord Date: 2013-07-31 Impact factor: 4.339

3. Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients.

Authors: M M Vellinga; J A Castelijns; F Barkhof; B M J Uitdehaag; C H Polman
Journal: Neurology Date: 2007-09-13 Impact factor: 9.910

4. Discontinuation of disease-modifying therapies in multiple sclerosis - Clinical outcome and prognostic factors.

Authors: Gabriel Bsteh; Julia Feige; Rainer Ehling; Michael Auer; Harald Hegen; Franziska Di Pauli; Florian Deisenhammer; Markus Reindl; Thomas Berger
Journal: Mult Scler Date: 2016-10-20 Impact factor: 6.312

5. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS.

Authors:
Journal: Lancet Date: 1998-11-07 Impact factor: 79.321

6. Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment.

Authors: Stacy Ellen Hatcher; Emmanuelle Waubant; Bardia Nourbakhsh; Elizabeth Crabtree-Hartman; Jennifer S Graves
Journal: JAMA Neurol Date: 2016-07-01 Impact factor: 18.302

7. Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study.

Authors: Ilya Kister; Tim Spelman; Raed Alroughani; Jeannette Lechner-Scott; Pierre Duquette; Francois Grand'Maison; Mark Slee; Alessandra Lugaresi; Michael Barnett; Pierre Grammond; Gerardo Iuliano; Raymond Hupperts; Eugenio Pucci; Maria Trojano; Helmut Butzkueven
Journal: J Neurol Neurosurg Psychiatry Date: 2016-06-13 Impact factor: 10.154

7 in total